High on-treatment platelet reactivity is associated with adverse cardiovascular events following percutaneous coronary intervention. In analyses based on areas under receiver operating characteristic curves, platelet reactivity tests have poor-to-fair ability to discriminate between patients who are at risk of ischemic events and those who are not. The optimal platelet reactivity test has yet to be determined, and no large, randomized trial to date has successfully demonstrated the effectiveness of tailoring antiplatelet medications according to the platelet reactivity of individual patients for improved clinical outcomes. Therefore, the present role for platelet reactivity monitoring is selective and limited. Copyright Remedica Medical Education and Publishing.
|Original language||English (US)|
|Number of pages||8|
|Journal||Acute Coronary Syndromes|
|State||Published - Sep 6 2011|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine